These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 30779635)

  • 21. Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.
    Wei YQ; Wang DG; Yang H; Cao H
    PLoS One; 2015; 10(7):e0132561. PubMed ID: 26147597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
    Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
    Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Another Step Toward CYP2C19 Genotype-Guided Therapy in Treatment With Dual Antiplatelet Therapy.
    Ten Berg JM; van den Broek WWA
    JACC Cardiovasc Interv; 2023 Apr; 16(7):826-828. PubMed ID: 37045503
    [No Abstract]   [Full Text] [Related]  

  • 24. Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: Exploring the Role of Genotype-Guided Therapy in Reducing Readmission Rates.
    Comanici M; Raja SG
    Am J Cardiol; 2023 Sep; 203():507-508. PubMed ID: 37500316
    [No Abstract]   [Full Text] [Related]  

  • 25. Cost-effectiveness of
    Fu Y; Zhang XY; Qin SB; Nie XY; Shi LW; Shao H; Liu J
    Pharmacogenomics; 2020 Jan; 21(1):33-42. PubMed ID: 31849282
    [No Abstract]   [Full Text] [Related]  

  • 26. The clinical effects of CYP2C19 *2 allele frequency on Palestinian patients receiving clopidogrel after percutaneous coronary intervention.
    Ayesh BM; Al-Astal IR; Yassin MM
    Int J Clin Pharm; 2019 Feb; 41(1):96-103. PubMed ID: 30656556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
    Ogawa H; Isshiki T; Kimura T; Yokoi H; Nanto S; Takayama M; Kitagawa K; Nishikawa M; Miyazaki S; Ikeda Y; Nakamura M; Tanaka Y; Saito S
    J Cardiol; 2016 Jul; 68(1):29-36. PubMed ID: 26521100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention.
    Borse MS; Dong OM; Polasek MJ; Farley JF; Stouffer GA; Lee CR
    Pharmacogenomics; 2017 Aug; 18(12):1155-1166. PubMed ID: 28745582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium.
    Verma SS; Bergmeijer TO; Gong L; Reny JL; Lewis JP; Mitchell BD; Alexopoulos D; Aradi D; Altman RB; Bliden K; Bradford Y; Campo G; Chang K; Cleator JH; Déry JP; Dridi NP; Fernandez-Cadenas I; Fontana P; Gawaz M; Geisler T; Gensini GF; Giusti B; Gurbel PA; Hochholzer W; Holmvang L; Kim EY; Kim HS; Marcucci R; Montaner J; Backman JD; Pakyz RE; Roden DM; Schaeffeler E; Schwab M; Shin JG; Siller-Matula JM; Ten Berg JM; Trenk D; Valgimigli M; Wallace J; Wen MS; Kubo M; Lee MTM; Whaley R; Winter S; Klein TE; Shuldiner AR; Ritchie MD;
    Clin Pharmacol Ther; 2020 Nov; 108(5):1067-1077. PubMed ID: 32472697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese patients.
    Tang N; Yin S; Sun Z; Xu X; Qin J
    Scand J Clin Lab Invest; 2015 May; 75(3):223-9. PubMed ID: 25594796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.
    Siasos G; Oikonomou E; Vavuranakis M; Kokkou E; Mourouzis K; Tsalamandris S; Zaromitidou M; Kioufis S; Tsigkou V; Deftereos S; Stefanadis C; Tousoulis D
    Cardiology; 2017; 137(2):104-113. PubMed ID: 28329746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia).
    Fedorinov DS; Mirzaev KB; Ivashchenko DV; Temirbulatov II; Sychev DA; Maksimova NR; Chertovskih JV; Popova NV; Tayurskaya KS; Rudykh ZA
    Drug Metab Pers Ther; 2018 Jun; 33(2):91-98. PubMed ID: 29738309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A case for genotype-guided de-escalation of antiplatelet therapy after percutaneous coronary angioplasty.
    Cavallari LH; Lee CR
    Future Cardiol; 2019 Jul; 15(4):251-254. PubMed ID: 31385522
    [No Abstract]   [Full Text] [Related]  

  • 34. Clopidogrel Pharmacogenetics in Iranian Patients Undergoing Percutaneous Coronary Intervention.
    Mahdieh N; Rabbani A; Firouzi A; Zahedmehr A; Hoseinimoghaddam M; Saedi S; Sanati H; Basiri H; Noohi F; Rabbani B; Maleki M
    Cardiovasc Toxicol; 2018 Oct; 18(5):482-491. PubMed ID: 29777510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of the
    Biswas M; Sukasem C; Khatun Kali MS; Ibrahim B
    Pharmacogenomics; 2022 Feb; 23(3):207-220. PubMed ID: 35042400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction between platelet-derived microRNAs and CYP2C19*2 genotype on clopidogrel antiplatelet responsiveness in patients with ACS.
    Peng L; Liu J; Qin L; Liu J; Xi S; Lu C; Yin T
    Thromb Res; 2017 Sep; 157():97-102. PubMed ID: 28734158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Results of genotype-guided antiplatelet therapy in patients who undergone percutaneous coronary intervention with stent.
    Sánchez-Ramos J; Dávila-Fajardo CL; Toledo Frías P; Díaz Villamarín X; Martínez-González LJ; Martínez Huertas S; Burillo Gómez F; Caballero Borrego J; Bautista Pavés A; Marín Guzmán MC; Ramirez Hernández JA; Correa Vilches C; Cabeza Barrera J
    Int J Cardiol; 2016 Dec; 225():289-295. PubMed ID: 27744205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genotype-guided treatment of oral P2Y
    Claassens DM; Ten Berg JM
    Pharmacogenomics; 2020 Jan; 21(2):83-86. PubMed ID: 31957547
    [No Abstract]   [Full Text] [Related]  

  • 39. Genotype-Guided Antiplatelet Therapy After Coronary Intervention in Patients With High Bleeding Risk　- Never Judge a Book by Its Cover.
    Iijima R
    Circ J; 2023 May; 87(6):764-766. PubMed ID: 37032075
    [No Abstract]   [Full Text] [Related]  

  • 40. Cost-effectiveness analysis of personalized antiplatelet therapy in patients with acute coronary syndrome.
    Jiang M; You JH
    Pharmacogenomics; 2016 May; 17(7):701-13. PubMed ID: 27167099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.